Real‐world tolerance and outcomes of oxaliplatin‐based adjuvant chemotherapy for stage III colon cancer—Does dose intensity matter?
Robert Yoon(Liverpool Hospital), Weng Ng(Sir Run Run Shaw Hospital), Stephanie Lim(Camden and Campbelltown Hospitals), Tara L. Roberts(Camden and Campbelltown Hospitals), Wei Chua(Liverpool Hospital), Kate Wilkinson(Liverpool Hospital), Ray Asghari(Bankstown Lidcombe Hospital), Nasreen Kadaan(Liverpool Hospital), Gabriel Gabriel(UNSW Sydney), Cheok Soon Lee(Liverpool Hospital)
Cited by 4
Related Papers
HIN-200 Proteins Regulate Caspase Activation in Response to Foreign Cytoplasmic DNA
|Science|2009|822
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial
|The Lancet Oncology|2023|663
AIM2 and NLRP3 inflammasomes activate both apoptotic and pyroptotic death pathways via ASC
|Cell Death and Differentiation|2013|507
The mammalian PYHIN gene family: Phylogeny, evolution and expression
|BMC Evolutionary Biology|2012|202
The Molecular Basis for the Lack of Immunostimulatory Activity of Vertebrate DNA
|The Journal of Immunology|2003|174